Back to today’s briefing

Story perspectives

FDA Approves Yeztugo: Game-Changer for HIV Prevention

7/25/2025

46 8

Summary

Story summary

The FDA has greenlit lenacapavir, known as Yeztugo, for HIV prevention, providing a groundbreaking option with twice-yearly injections that boast an impressive 89% effectiveness over daily pills. However, its hefty $28,218 price tag and unclear insurance support could hinder access, especially for vulnerable communities. Meanwhile, Europe is also considering its approval.

1 of 1

Story summary

The FDA has greenlit lenacapavir, known as Yeztugo, for HIV prevention, providing a groundbreaking option with twice-yearly injections that boast an impressive 89% effectiveness over daily pills. However, its hefty $28,218 price tag and unclear insurance support could hinder access, especially for vulnerable communities. Meanwhile, Europe is also considering its approval.